SCHEMBL5188581

SCHEMBL5188581

O=C(O)c1c(F)ccc2cc[nH]c12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPRC P08575 1/20 0.55
PTPN2 P17706 1/20 0.55
PTPN1 P18031 1/20 0.55
PTPRB P23467 1/20 0.55
PTPRE P23469 1/20 0.55
PTPN6 P29350 1/20 0.55
TNF P01375 1/20 0.52
RIPK1 Q13546 1/20 0.52
KEAP1 Q14145 1/20 0.49
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
ENPP2 Q13822 1/20 0.44
HSD17B10 Q99714 1/20 0.44
PDPK1 O15530 1/20 0.40
MGLL Q99685 1/20 0.36
BACE1 P56817 1/20 0.35
ESR1 P03372 1/20 0.35
ACLY P53396 1/20 0.35
GPR84 Q9NQS5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31438296 0.81 PTPRC (0.58) PTPRCPTPN2PTPN1PTPRBPTPRE
SCHEMBL1397914 0.80 TNF (0.50) PTPRCPTPN2PTPN1PTPRBPTPRE
SCHEMBL5186145 0.79 PTPRC (0.45) PTPRCPTPN2PTPN1PTPRBPTPRE
SCHEMBL4084024 0.78 PTPRC (0.55) PTPRCPTPN2PTPN1PTPRBPTPRE
SCHEMBL12583956 0.76 CA12 (0.42) TNFRIPK1KDM4EALDH1A1HPGD
SCHEMBL23538104 0.74 KEAP1 (0.58) PTPRCPTPN2PTPN1PTPRBPTPRE
SCHEMBL1397792 0.74 PTPRC (0.44) PTPRCPTPN2PTPN1PTPRBPTPRE
SCHEMBL621046 0.73 PTPRC (0.43) PTPRCPTPN2PTPN1PTPRBPTPRE
SCHEMBL3309453 0.72 CES2 (0.50) KDM4EALDH1A1HPGDHSD17B10TTR
SCHEMBL30048528 0.72 CES2 (0.50) KDM4EALDH1A1HPGDHSD17B10TTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3856179-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-05-13 EP disclosed
US-20240327410-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2024-10-03 US disclosed
CN-113164458-B Monoacylglycerol lipase modulators 詹森药业有限公司 2024-09-13 CN disclosed
US-11993601-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV 2024-05-28 US disclosed
US-20230242531-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-08-03 US disclosed
US-11597728-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-03-07 US disclosed
US-20220315583-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2022-10-06 US disclosed
EP-3856179-A1 MONOACYLGLYCEROL LIPASE MODULATORS Janssen Pharmaceutica N.V. (BE) 2021-08-04 EP disclosed
CN-113164458-A Monoacylglycerol lipase modulators 詹森药业有限公司 2021-07-23 CN disclosed
US-20200102311-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2020-04-02 US disclosed
WO-2020065614-A1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2020-04-02 WO disclosed
CN-1993323-B Indole, indazole or indoline derivatives HOFFMANN LA ROCHE 2011-04-20 CN disclosed
US-7259183-B2 Indole, indazole and indoline derivatives as CETP inhibitors HOFFMANN-LA ROCHE INC. (US) 2007-08-21 US disclosed
CN-1993323-A Indole, indazole or indoline derivatives HOFFMANN LA ROCHE (CH) 2007-07-04 CN disclosed
EP-1776338-A1 INDOLE, INDAZOLE OR INDOLINE DERIVATIVES F. Hoffmann-Roche AG (CH) 2007-04-25 EP disclosed
US-20060030613-A1 Indole, indazole and indoline derivatives as CETP inhibitors F. HOFFMANN-LA ROCHE AG (CH) 2006-02-09 US disclosed
WO-2006013048-A1 INDOLE, INDAZOLE OR INDOLINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2006-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030613-A1 Indole, indazole and indoline derivatives as CETP inhibitors CETP, NAT1, MTTP PTPRC 3690/4885PTPN2 4025/4885PTPN1 2788/4885
US-20230242531-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP PTPRC 2500/4885PTPN2 3841/4885PTPN1 3968/4885
US-11993601-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP PTPRC 2500/4885PTPN2 3841/4885PTPN1 3968/4885
US-20200102311-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP PTPRC 2500/4885PTPN2 3841/4885PTPN1 3968/4885
US-11597728-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP PTPRC 2500/4885PTPN2 3841/4885PTPN1 3968/4885
US-20240327410-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP PTPRC 2500/4885PTPN2 3841/4885PTPN1 3968/4885
US-20220315583-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP PTPRC 2500/4885PTPN2 3841/4885PTPN1 3968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.